ENGLEWOOD, Colo., July 2, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company received an update from Tricare that the temporary payment suspension will continue."As we previously announced, we were notified of a temporary suspension of payments from our largest insurance customer, Tricare," said Thomas Sandgaa ...

Company Leadership Change - Zynex, Inc. announced the appointment of Steven Dyson as Chief Executive Officer, effective August 18, 2025 [1] - Thomas Sandgaard, the founder and Chairman of the Board since 1996, will continue to be actively involved in the company [2] Executive Experience - Steven Dyson brings over 25 years of experience in the medical technology sector, with a strong background in private equity and leadership roles in various healthcare companies [3] - His previous experience includes significant roles in companies such as KCI, Rodenstock, Healthium Medtech, Unilabs, and Neuraxpharm [3] Strategic Focus - The company aims to refocus its business strategy towards a more optimized payer mix and to return to a strong growth trajectory under Dyson's leadership [5] - Dyson expressed enthusiasm about leading Zynex and emphasized the strong foundation built by Sandgaard [5] Company Overview - Zynex develops, manufactures, markets, and sells medical devices for pain management and rehabilitation, as well as non-invasive monitoring systems for hospitals [10]